Delayed Treatment With Nicotinamide (Vitamin B 3 ) Improves Neurological Outcome and Reduces Infarct Volume After Transient Focal Cerebral Ischemia in Wistar Rats
- 1 July 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 31 (7) , 1679-1685
- https://doi.org/10.1161/01.str.31.7.1679
Abstract
Background and Purpose—We have previously shown that nicotinamide (NAm) acutely reduces brain infarction induced by permanent middle cerebral artery occlusion (MCAo) in rats. In this study, we investigate whether NAm may protect against ischemia/reperfusion injury by improving sensory and motor behavior as well as brain infarction volumes in a model of transient focal cerebral ischemia. Methods—Forty-eight male Wistar rats were used, and transient focal cerebral ischemia was induced by MCAo for 2 hours, followed by reperfusion for either 3 or 7 days. Animals were treated with either intraperitoneal saline or NAm (500 mg/kg) 2 hours after the onset of MCAo (ie, on reperfusion). Sensory and motor behavior scores and body weight were obtained daily, and brain infarction volumes were measured on euthanasia. Results—Relative to treatment with saline, treatment with NAm (500 mg/kg IP) 2 hours after the onset of transient focal cerebral ischemia in Wistar rats significantly improved sensory (38%, PPPPP=0.09) at 7 days after MCAo. Conclusions—NAm is a robust neuroprotective agent against ischemia/reperfusion-induced brain injury in rats, even when administered up to 2 hours after the onset of stroke. Delayed NAm treatment improved both anatomic and functional indices of brain damage. Further studies are needed to clarify whether multiple doses of NAm will improve the extent and duration of this neuroprotective effect and to determine the mechanism(s) of action underlying the neuroprotection observed. Because NAm is already used clinically in large doses and has few side effects, these results are encouraging for the further examination of the possible use of NAm as a therapeutic neuroprotective agent in the clinical treatment of acute ischemic stroke.Keywords
This publication has 29 references indexed in Scilit:
- Ischemic Brain Injury is Mediated by the Activation of Poly(ADP-Ribose)PolymeraseJournal of Cerebral Blood Flow & Metabolism, 1997
- Neuroprotective Effects of Inhibiting Poly(ADP-Ribose) Synthetase on Focal Cerebral Ischemia in RatsJournal of Cerebral Blood Flow & Metabolism, 1997
- Very Delayed Infarction after Mild Focal Cerebral Ischemia: A Role for Apoptosis?Journal of Cerebral Blood Flow & Metabolism, 1996
- Traumatic neuroprotection with inhibitors of nitric oxide and ADP-ribosylationBrain Research, 1996
- Protection against CNS Ischemia by Temporary Interruption of Function-Related Processes of NeuronsJournal of Cerebral Blood Flow & Metabolism, 1995
- Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonateAnnals of Neurology, 1994
- A Semiautomated Method for Measuring Brain Infarct VolumeJournal of Cerebral Blood Flow & Metabolism, 1990
- Angiogenic potency of nucleotide metabolites: Potential role in ischemia-induced vascular growthJournal of Molecular and Cellular Cardiology, 1989
- Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats.Stroke, 1986
- Experimental studies of ischemic brain edemaJapanese Journal of Stroke, 1986